Allergan Hits Alcon With Combigan Patents

Law360, New York (November 9, 2009, 12:52 PM EST) -- Allergan Inc. continues to pounce on rival drugmakers' attempts to market generic versions of Combigan, most recently accusing Alcon Inc. of infringing three patents for the glaucoma treatment.

The complaint, lodged Friday in the U.S. District Court for the Eastern District of Texas, asserts three patents in response to Alcon’s bid for regulatory approval of a knock-off version of the Combigan eye care solution.

Allergan claims the Swiss eye care company filed an abbreviated new drug application with the U.S. Food and Drug Administration in September,...
To view the full article, register now.